Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified
Status:
Unknown status
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
Antimicrobial resistance is a significant challenge facing global healthcare. The unnecessary
use of antibiotics is a key driver in the development of antibiotic resistance. Cystic
Fibrosis (CF) represents a unique disease model to study bacterial resistance and to explore
therapeutic strategies for same, as chronic lung infection overlaps with acute lung
exacerbation's caused by a multitude of organisms. With time, chronic polymicrobial infection
develops, with the most dominant infecting organism being Pseudomonas aeruginosa. In acute CF
infections, empiric intravenous antibiotics are usually given for two weeks. Recurrent
infections and treatments result in increasing antimicrobial resistance, and alterations in
pathogen host interactions in the lung and gut flora. Next-generation DNA sequencing
technology now offers DNA-based personalised diagnostics and treatment strategies. Enhancing
our knowledge of the microbiome allows the use of stratified targeted antibacterial therapy
that can be compared with standard empirical antibacterial therapy currently used. Cystic
Fibrosis Microbiome-determined Antimicrobial Therapy Trial in Exacerbations: Results
Stratified (CFMATTERS) will provide a randomized multi-centre controlled trial of
microbiome-derived antimicrobial treatments versus current empirical therapy.
Phase:
N/A
Details
Lead Sponsor:
University College Cork
Collaborators:
Assistance Publique - Hôpitaux de Paris Clininfo S.A. European Union GABO:mi Katholieke Universiteit Leuven KU Leuven Papworth Hospital Papworth Hospital NHS Foundation Trust Queen's University, Belfast Teagasc University Hospital Heidelberg University of Dundee University of Paris 5 - Rene Descartes University of Washington